Ongoing study into novel anti-HER2 antibodies, innovative ADCs, and promising combination therapies, such as PI3K inhibitors and CDK4/6 inhibitors, holds great promise for advancing treatment outcomes in HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast cancer.